

# Anders Bach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9243204/publications.pdf>

Version: 2024-02-01

51  
papers

2,094  
citations

293460

24  
h-index

263392

45  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3002  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3266-3305.	2.9	5
2	Identification of Novel Fragments Binding to the PDZ1 Domain of PSD95. <i>ChemMedChem</i> , 2021, 16, 949-954.	1.6	1
3	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery. <i>ChemMedChem</i> , 2021, 16, 1737-1740.	1.6	7
4	Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4623-4661.	2.9	30
5	GHB analogs confer neuroprotection through specific interaction with the CaMKII $\alpha$ hub domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	31
6	Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist. <i>Molecular Metabolism</i> , 2021, 49, 101207.	3.0	9
7	Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1156-1177.	2.9	25
8	The dynamics of linear polyubiquitin. <i>Science Advances</i> , 2020, 6, .	4.7	38
9	Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood-Brain Barrier Adherence, Uptake, and Permeation. <i>Pharmaceutics</i> , 2020, 12, 661.	2.0	22
10	A high-affinity, bivalent PDZ domain inhibitor complexes PICK1 to alleviate neuropathic pain. <i>EMBO Molecular Medicine</i> , 2020, 12, e11248.	3.3	20
11	A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8028-8052.	2.9	66
12	Molecular architecture of the Jumonji C family histone demethylase KDM5B. <i>Scientific Reports</i> , 2019, 9, 4019.	1.6	16
13	Selectivity, efficacy and toxicity studies of UCCB01-144, a dimeric neuroprotective PSD-95 inhibitor. <i>Neuropharmacology</i> , 2019, 150, 100-111.	2.0	21
14	Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8088-8103.	2.9	71
15	PSD-95 uncoupling from NMDA receptors by Tat-N-dimer ameliorates neuronal depolarization in cortical spreading depression. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1820-1828.	2.4	27
16	Targeting Oxidative Stress in Stroke. <i>Springer Series in Translational Stroke Research</i> , 2017, , 203-250.	0.1	8
17	Effects of the dimeric PSD-95 inhibitor UCCB01-144 on functional recovery after fimbria-fornix transection in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 161, 62-67.	1.3	2
18	Effects of Dimeric PSD-95 Inhibition on Excitotoxic Cell Death and Outcome After Controlled Cortical Impact in Rats. <i>Neurochemical Research</i> , 2017, 42, 3401-3413.	1.6	5

#	ARTICLE	IF	CITATIONS
19	<i>In vitro</i> and <i>in vivo</i> effects of a novel dimeric inhibitor of PSD-95 on excitotoxicity and functional recovery after experimental traumatic brain injury. <i>European Journal of Neuroscience</i> , 2017, 45, 238-248.	1.2	14
20	Effects of the dimeric PSD-95 inhibitor UCCB01-144 in mouse models of pain, cognition and motor function. <i>European Journal of Pharmacology</i> , 2016, 780, 166-173.	1.7	6
21	Acid Ceramidase in Melanoma. <i>Journal of Biological Chemistry</i> , 2016, 291, 2422-2434.	1.6	72
22	Design and synthesis of triazole-based peptidomimetics of a PSD-95 PDZ domain inhibitor. <i>MedChemComm</i> , 2016, 7, 531-536.	3.5	8
23	Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. <i>Scientific Reports</i> , 2015, 5, 12157.	1.6	29
24	Rigidified Clicked Dimeric Ligands for Studying the Dynamics of the PDZ1 Supramodule of PSD-95. <i>ChemBioChem</i> , 2015, 16, 64-69.	1.3	15
25	Benzoxazolone Carboxamides as Potent Acid Ceramidase Inhibitors: Synthesis and Structure-Activity Relationship (SAR) Studies. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9258-9272.	2.9	29
26	Design, Synthesis, and Characterization of Fatty Acid Derivatives of a Dimeric Peptide-Based Postsynaptic Density-95 (PSD-95) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1575-1580.	2.9	10
27	Targeting Protein-Protein Interactions with Trimeric Ligands: High Affinity Inhibitors of the MAGUK Protein Family. <i>PLoS ONE</i> , 2015, 10, e0117668.	1.1	17
28	Benzoxazolone Carboxamides: Potent and Systemically Active Inhibitors of Intracellular Acid Ceramidase. <i>Angewandte Chemie - International Edition</i> , 2014, 54, n/a-n/a.	7.2	23
29	UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: Comparison with the NMDA receptor antagonist MK-801. <i>Neuropharmacology</i> , 2013, 67, 193-200.	2.0	20
30	Energetic Pathway Sampling in a Protein Interaction Domain. <i>Structure</i> , 2013, 21, 1193-1202.	1.6	38
31	Interaction partners of PSD-93 studied by X-ray crystallography and fluorescence polarization spectroscopy. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 587-594.	2.5	5
32	PDZ Domain-Mediated Interactions of G Protein-Coupled Receptors with Postsynaptic Density Protein 95: Quantitative Characterization of Interactions. <i>PLoS ONE</i> , 2013, 8, e63352.	1.1	11
33	A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3317-3322.	3.3	162
34	Side-Chain Interactions Form Late and Cooperatively in the Binding Reaction between Disordered Peptides and PDZ Domains. <i>Journal of the American Chemical Society</i> , 2012, 134, 599-605.	6.6	41
35	Ligand binding by PDZ domains. <i>BioFactors</i> , 2012, 38, 338-348.	2.6	66
36	Cell-Permeable and Plasma-Stable Peptidomimetic Inhibitors of the Postsynaptic Density-95/N-Methyl-D-Aspartate Receptor Interaction. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1333-1346.	2.9	81

#	ARTICLE	IF	CITATIONS
37	Expedient Synthesis of 1,3-Substituted Benzene Peptidomimetics. <i>Synthesis</i> , 2011, 2011, 807-815.	1.2	2
38	Biophysical Characterization of the Complex between Human Papillomavirus E6 Protein and Synapse-associated Protein 97. <i>Journal of Biological Chemistry</i> , 2011, 286, 3597-3606.	1.6	18
39	A Fluorescence Polarization Based Screening Assay for Identification of Small Molecule Inhibitors of the PICK1 PDZ Domain. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2011, 14, 590-600.	0.6	12
40	Unique Interaction Pattern for a Functionally Biased Ghrelin Receptor Agonist. <i>Journal of Biological Chemistry</i> , 2011, 286, 20845-20860.	1.6	42
41	Deciphering the Kinetic Binding Mechanism of Dimeric Ligands Using a Potent Plasma-stable Dimeric Inhibitor of Postsynaptic Density Protein-95 as an Example. <i>Journal of Biological Chemistry</i> , 2010, 285, 28252-28260.	1.6	29
42	Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 413-418.	3.3	100
43	A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors. <i>Journal of Biological Chemistry</i> , 2010, 285, 3973-3985.	1.6	126
44	Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1. <i>Organic and Biomolecular Chemistry</i> , 2010, 8, 4281.	1.5	31
45	Design and Synthesis of Highly Potent and Plasma-stable Dimeric Inhibitors of the PSD-95-NMDA Receptor Interaction. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 9685-9689.	7.2	55
46	Detecting Protein-Protein Interactions in Living Cells: Development of a Bioluminescence Resonance Energy Transfer Assay to Evaluate the PSD-95/NMDA Receptor Interaction. <i>Neurochemical Research</i> , 2009, 34, 1729-1737.	1.6	7
47	A Sequential Binding Mechanism in a PDZ Domain. <i>Biochemistry</i> , 2009, 48, 7089-7097.	1.2	46
48	Modified Peptides as Potent Inhibitors of the Postsynaptic Density-95/N-Methyl-D-Aspartate Receptor Interaction. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6450-6459.	2.9	61
49	Ghrelin Receptor Inverse Agonists: Identification of an Active Peptide Core and Its Interaction Epitopes on the Receptor. <i>Molecular Pharmacology</i> , 2006, 70, 936-946.	1.0	82
50	Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling. <i>Molecular Endocrinology</i> , 2005, 19, 2400-2411.	3.7	111
51	Common Structural Basis for Constitutive Activity of the Ghrelin Receptor Family. <i>Journal of Biological Chemistry</i> , 2004, 279, 53806-53817.	1.6	303